Hot Investor Mandate 3: Pharma Firm Licenses High Potential Early Stage Assets and Therapeutic Platforms

1 Jun

A pharmaceutical company based in Shanghai, China is actively engaged in R&D, sales, and manufacturing of pharmaceutical products. The company has recently developed a strategy to expand its current pipeline of generics by in-licensing of high-potential assets and developing global partnerships and strategic alliances with companies developing innovative medicines. The company is very interested in early therapeutic assets and is actively seeking partnering opportunities.

The firm is actively seeking all innovative products in the therapeutics space including platform technologies. While the company generally takes an opportunistic approach, the 3 main areas of interest are gastrointestinal diseases, respiratory diseases, and oncology. The company has strong domestic expertise in these specific fields and can act as a strong partner to help their assets of interest move through the pipeline and enter commercialization.

The firm seeks to partner with companies that would be interested in entering the China market, and deemed to have the strong potential to do well in China. The company will strongly seek distribution rights for in-licensed products.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: